Since October 2013, Elaine Del-Bel has been a Full Professor of Physiology at FORP-University of Sao Paulo and an A1 Researcher at CNPQ. She has a master's and doctorate in Pharmacology from FMRP-USP. The postdoctoral fellowship was held in England at Manchester University. He performed short term internships and developed projects in collaboration with Prof. J. Nicholls, (SISSA-Trieste Italy); Prof. Francisco Fernandez de Miguel (Autonomous University of Mexico); Prof. W. Sthumer (Institute Max Planck for Experimental Medicine, Göttingen, Germany); Dr. R. Raisman Vozari (INSERM, Paris, France); Prof. F. Kirchhoff (University of Homburg- Saarland-Germany). Tested the hypothesis that nitric oxide, cannabidiol and antibiotics act as neuroprotective agents in Parkinson's disease and consequences of treatment with the dopamine precursor (Levodopa); in Schizophrenia using the pre-pulse inhibition reaction paradigm and the sensory-motor impairment produced by amphetamine. He showed that the blockade of nitric oxide synthesis enzymes as well as treatment with the antibiotic doxycycline, are neuroprotectective in damaging the dopaminergic system and decrease the deleterious effect of Levodopa treatment in animals with the parkinsonian syndrome. He also described the neuroprotective effect of cannabidiol and nitric oxide on amphetamine-induced sensory-motor impairment. Major ongoing projects in the lab are Study of Neurodegenerative and Neuropsychiatric Diseases; Experimental Parkinson's; Analysis of neuroinflammation in Levodopa-induced dyskinesia; Experimental Schizophrenia: the nitrergic and endocannabinoid system in sensory-motor function. He has 199 published papers (Web of Science -H-Index 36 Google). She has research projects funded by FAPESP and CNPQ CAPES and IBRO. He has received national and international awards. In 2018 she received the Bernice Grafstein Award for Outstanding Accomplishments in Mentoring (SfN-USA). In 2020 she was identified as one of the 50 women protagonists of Science in Brazil, in the area of Biological Sciences (Open Box Project of Science held with support from Serrapilheira Institute). In 2014 she received the USP Award - PhD thesis, Health area (F. Padovan-Neto). He is a member of the Latin American Academy of Sciences (ACAL) since 2020. He has lectured/participated in international symposia: at the prestigious Royal Society (UK), Neurotoxicity Society (Chile, Spain), IBRO World Congress (RJ), University of Chicago (USA), UNAM- Mexico, Basal Ganglia Society (MX), University of Saarland-Germany, Max-Planck-Göttingen Institute, The Physiological Society (UK), Society for Neurosciences (USA); Dopamine2016/Austria, Central European Biomedical Congress, Poland. He is part of the IBRO-VLT team and has taught courses in Africa, Brazil, Colombia, Ecuador, Bolivia, Peru, India and Paraguay. She is President of the Federation of Latin America and Caribbean Societies for Neuroscience (FALAN).Vice-head of the Department Department of Basic and Oral Biology, University of Sao Paulo, Dentistry School of Ribeirao Preto.I am working with the World Women in Neuroscience, part of the Scientific Advocacy Committee. The goal of this committee is to promote the well-being and career advancement of WWN members by developing and implementing activities that advance the group?s mission and vision. To learn more and get involved, email world.women.in.neuroscience@gmail.com. Also, I am part of the ALBA network team: Alba Advisor Founded by a group of leading scientists, the ALBA Network aims to promote equity and diversity in the brain sciences. http://www.alba.network/about-us#our-team (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
There is evidence in the literature that the inflammatory process may contribute to and / or exacerbate the clinical manifestations of Parkinson's disease and dyskinesias (abnormal involuntary movements) associated with Parkinson's disease and disease therapy. There is a great socio-economic impact of these disorders on the lives of patients and their families. Thus, it is necessary to ha…
The need to develop new therapeutic targets for the treatment of neuropsychiatric disorders is a consensus in the scientific literature. Endocannabinoids (eCBs) and nitric oxide (NO) have been proposed as two of these possible targets. Studies from our group have disclosed the therapeutic potential of drugs that interfere with these two atypical neurotransmitters in anxiety, depressive, p…
L-3, 4-dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson´s disease but can induce debilitating abnormal involuntary movements (dyskinesia). The precise mechanisms underlying the process remain to be clarified. However, some recent studies have suggested that L-DOPA-induced dyskinesia may be related to a "pro-inflammatory" environment in the striatum. Our group …
(Only some records are available in English at this moment)
The brain-gut axis is a bidirectional communication channel, and the intestinal microbiota has a great influence on this channel. Changes in the microbiota of the upper and lower gastrointestinal tract have been documented in Parkinson's disease (PD). Although there is intercommunication between the intestinal microbiota and the host's inflammatory response, the causal relationship betwee…
Changes in the upper and lower gastrointestinal tract microbiome have been documented in Parkinson's disease (PD). The oral microbiota is scarcely studied in this context, despite its fundamental role in maintaining oral and systemic health and the evidence that Parkinsonian individuals have a higher prevalence of periodontitis. Although there is intercommunication between the periodontal…
The introduction of drugs with antipsychotic activity in the 1950s allowed the treatment of schizophrenia symptoms, such as delusions and hallucinations. The chronicity of these treatments induces extrapyramidal effects such as tardive dyskinesia, characterized by involuntary and stereotyped orofacial movements of great functional and social impact. Tardive dyskinesia has been the subject…
(Only some records are available in English at this moment)
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, and its occurrence and progression have been extensively studied. However, the pathogenesis of PD is still far from fully understood. Neuroinflammation is one of the neurobiological characteristics of PD pathology, with this brain-mediated inflammatory response primarily mediated by the…
Neuroinflammation process is characterized by interaction between neurons and cells of immune system, such as cytokines, chemokines, inflammatory cells, matrixmetalloproteinases (MMPs), reactive oxygen species (ROS) and glial cells. This neuroimmune interaction is presents in Schizophrenia and Parkinson's disease (PD).Parkinson's disease is the second most common neurodegenerative disorde…
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons whose cause is still unknown. The most effective treatment for PD motor symptoms is through administration of L-DOPA. However, the chronicity of this treatment leads to the development L-DOPA-induced dyskinesia (LID). Our group demonstrated the presence of activated astrocytes, microglia and increased expression…
(Only some records are available in English at this moment)
| 23 / 11 | Completed research grants |
| 54 / 24 | Completed scholarships in Brazil |
| 7 / 7 | Completed scholarships abroad |
| 84 / 42 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID